Taking a break from hormone-blocking prostate cancer treatments once the cancer seems to be stabilized is not equivalent to continuing therapy, a new large-scale international study finds.
[More]
Angela H. Brodie, Ph.D., a University of Maryland scientist whose research paved the way for a new class of drugs widely used to treat breast cancer patients around the world, has been selected by the American Association for Cancer Research as a fellow of the newly created AACR Academy.
[More]
DART Therapeutics Inc., an innovative, new-model biotechnology firm focused on developing therapies for Duchenne muscular dystrophy, announced today that it is developing a SARM drug candidate obtained from Belgium-based Galapagos NV.
[More]
Despite the high erectile dysfunction prevalence most patients receive no treatment, according to a new US study, presented at the 28th Annual EAU Congress. Undertreatment of ED continues to be common, even though the treatments have a proven efficacy and quality of life impact.
[More]
As part of an EU-supported IMI-PREDECT consortium, a Dutch study showed that anti-androgenic properties of the drug abiraterone may provide an additional mechanism of action in blocking tumour growth of castration resistant prostate cancer (CRPC).
[More]
GTx, Inc. today announced that the journal, The Lancet Oncology, has published online ahead of its April print edition the results from GTx's randomized, double-blind, placebo-controlled Phase 2 clinical trial of enobosarm to assess its effects on muscle wasting and physical function in patients with cancer.
[More]
Determining the androgen content in prostate tissue could predict patients’ responses to androgen deprivation therapy and the risk for castration-resistant prostate cancer, show study findings.
[More]
Androgen deprivation therapy for prostate cancer hampers glycemic control in men with diabetes, report researchers.
[More]
Contrary to current belief, routine newborn screening improves the detection of the lethal form of congenital adrenal hyperplasia (CAH) in girls as well as boys, saving lives in both sexes, according to a unique study of CAH during the last 100 years published Online First in The Lancet Diabetes and Endocrinology.
[More]
Ampio Pharmaceuticals, Inc. announced oral dosing of the first patient in a 505(b)(2) clinical trial of the investigational drug Optina in diabetic macular edema.
[More]
A natural, nontoxic product called genistein-combined polysaccharide, or GCP, which is commercially available in health stores, could help lengthen the life expectancy of certain prostate cancer patients, UC Davis researchers have found.
[More]
While prostate cancer is the most common cancer in elderly Western men it also, but more rarely, strikes patients aged between 35 and 50. Scientists at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, in collaboration with several other research teams in Germany, have discovered that such early-onset prostate cancers are triggered by a different mechanism from that which causes the disease at a later age.
[More]
University of Granada researchers have designed a guideline for physicians and patients on the Androgen Insensitivity Syndrome (AIS), a rare disease that makes the subject develop reverse sex, which occurs when a subject looks like a woman but has male genes.
[More]
Testosterone and its derivatives could constitute an efficient treatment against myelin diseases such as multiple sclerosis, reveals a study by researchers from the Laboratoire d'Imagerie et de Neurosciences Cognitives, in collaboration in particular with the "Neuroprotection et Neurorégénération: Molécules Neuroactives de Petite Taille" unit.
[More]
Low prediagnostic levels of circulating sex hormones are not associated with more aggressive disease in patients with prostate cancer, say US researchers.
[More]
Low prediagnostic levels of circulating sex hormones are not associated with more aggressive disease in patients with prostate cancer, say US researchers.
[More]
An independent panel convened by the National Institutes of Health has concluded that the name of a common hormone disorder in women, polycystic ovary syndrome (PCOS), causes confusion and is a barrier to research progress and effective patient care. The current name focuses on a criterion - ovarian cysts - which is neither necessary nor sufficient to diagnose the syndrome.
[More]
Ampio Pharmaceuticals, Inc. announced today that the FDA has accepted the Company's IND for Optina™ for the treatment of diabetic macular edema (DME). Ampio plans to commence enrollment in a clinical trial in the first quarter of 2013. The FDA granted Optina™ 505(b)(2) status in July, 2012. Drugs designated under this pathway can be approved on a single trial.
[More]
In what is believed to be the first study to describe the impact on men with a 'high' risk of bone fracture who are receiving long-term androgen deprivation therapy (ADT) for prostate cancer, new research from The Cancer Institute of New Jersey shows this population to have a higher fracture incidence following treatment completion.
[More]
Men choosing prostate cancer treatment should be informed about the small risk for penis shrinkage, say US researchers who believe discussing the rare side effect could reduce the chance for patient regret.
[More]